A New Era of Healing
We are pioneering the synthesis of altered states of consciousness and intelligent digital therapeutics. A completely new paradigm to treat the root cause of mental illness.
The Need for a New Paradigm
Current psychiatric modalities are failing to stem the rising tide of complex mental health crises. The introduction of psychedelic medicine offers immense promise, but subjective human facilitation lacks scalability, objective measurement, and consistent clinical guardrails.
Entity Therapeutics is addressing the world's most intractable conditions: Post-Traumatic Stress Disorder (PTSD), Treatment-Resistant Depression (TRD), and Addiction. By layering an advanced conversational AI and biofeedback system over the psychedelic experience, we are transforming unpredictable journeys into targeted, objective, and highly effective therapeutic arcs.
We are developing algorithms specifically optimized to altered states induced by Psilocybin, LSD, and Ketamine.
Clinical Pipeline
We are at the starting point of a revolution. Our initial focus is developing and validating our core beta application across multiple indications.
| Indication |
Discovery
Pre-Clinical
Pilot Study
Pivotal Trial
FDA Clearance
|
|---|---|
| PTSD | |
| Treatment-Resistant Depression | |
| Addiction (SUD) |